Planning for the launch of a new drug or medical device usually includes conversations about price setting and payer negotiations. Emerging biopharma and medical technology companies are increasingly required to think about these conversations at ever-earlier stages of development.
This early work can substantially affect the value of a new medicine or medical device during discussions with potential investors, partners, or acquirers. Depending on the target market, a substantial component of due diligence efforts will focus on access and how the product will be reimbursed.
